Products
Pre-made Rilotumumab benchmark antibody ( Whole mAb, anti-HGF therapeutic antibody, Anti-DFNB39/F-TCF/HPTA/SF Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-483
Pre-Made Rilotumumab biosimilar, Whole mAb, Anti-HGF Antibody: Anti-DFNB39/F-TCF/HPTA/SF therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Rilotumumab (previously AMG102) is a human monoclonal antibody designed for the treatment of solid tumors.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-483-1mg | 1mg | 3090 | Inquiry | Inquiry |
Size： 1mg | 10mg | 100mg
Description
| Products Name (INN Index) | Pre-Made Rilotumumab biosimilar, Whole mAb, Anti-HGF Antibody: Anti-DFNB39/F-TCF/HPTA/SF therapeutic antibody |
| INN Name | Rilotumumab |
| Target | HGF |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2009 |
| Year Recommended | 2010 |
| Companies | Amgen;Astellas Pharma |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Colorectal cancer;Gastric cancer;Glioma;Prostate cancer;Renal cancer;Small cell lung cancer;Solid tumours |
| Development Tech | Abgenix XenoMouse |
<